- Genomic Disease Burden Markers, PD-L1 Expression Predictive of pOR With Neoadjuvant Gem-iDRS ± Cetrelimab in MIBCA biomarker analysis of SunRISe-4 found that high baseline TMB, GBD, and PD-L1 expression were associated with pathologic overall response to the regimen.onclive · 2mo ago↗ source
- Dr Croll on Radiographic Size Change vs irRVT After Neoadjuvant Therapy in RCCBenjamin Croll, MD, discusses findings from a study of the correlation between radiographic response and pathologic response in RCC.onclive · 2mo ago↗ source
- FDA Approves T-DXd for Early-Stage HER2+ Breast CancerThe FDA approved trastuzumab deruxtecan for the adjuvant and neoadjuvant treatment of select early-stage HER2-positive breast cancer.